Therapeutic effect of TRC105 and decitabine combination in AML xenografts

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, often characterized by poor prognosis following standard induction therapy. The hypomethylating agent decitabine (DAC) is an alternative treatment for elderly and relapsed/refractory AML patients, yet responses following DAC monot...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Heliyon
Hlavní autoři: Baik, June, Felices, Martin, Yingst, Ashley, Theuer, Charles P., Verneris, Michael R., Miller, Jeffrey S., Perlingeiro, Rita
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2020
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7566100/
https://ncbi.nlm.nih.gov/pubmed/33088975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.heliyon.2020.e05242
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky